New York-based AI biotech company Envisagenics entered into a multi-year collaboration with big pharma company Bristol-Myers Squibb (BMS) to accelerate the identification of novel oncology targets. The terms and financial details of the agreement have not been disclosed.
The duo will combine Envisagenics’s AI platform SpliceCore and BMS’s drug development expertise to identify alternative splicing-derived targets to join BMS’s existing oncology pipeline.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.